Profil
Gerard A.
Wills is Chief Financial Officer of Multicell Technologies, Inc. He was Chief Financial Officer of Immusol, Inc. from 2004 to January 2006.
From 2001 to 2003, he was Vice President of Finance and Chief Financial Officer of Nanogen, Inc. From 1999 to 2001, he was Vice President of Finance and Chief Financial Officer of Trega Biosciences, Inc. He received his Bachelor of Business Administration degree in accountancy from the University of Notre Dame.
Anciens postes connus de Gerard A. Wills
| Sociétés | Poste | Fin |
|---|---|---|
| NGEN INC | Directeur Financier/CFO | 01/01/2003 |
Trega Biosciences, Inc.
 Trega Biosciences, Inc. BiotechnologyHealth Technology Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG | Directeur Financier/CFO | 01/01/2001 |
| MULTICELL TECHNOLOGIES, INC. | Directeur Financier/CFO | - |
Formation de Gerard A. Wills
| University of Notre Dame | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MULTICELL TECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Trega Biosciences, Inc.
Trega Biosciences, Inc. BiotechnologyHealth Technology Trega Biosciences, Inc. was a drug discovery company, utilizing combinatorial chemistry and other technologies to pursue the discovery of novel, small-molecule drug therapies. The company leveraged its technology platform by entering into pharmaceutical alliances, enabling partners to access its technologies in exchange for licensing fees and potential milestone payments and royalties or by establishing joint-discovery alliances with biotechnology companies. The company used its drug discovery technologies in its internal development programs. It was headquartered in San Diego, CA. The compnay was acquired by LION bioscience AG | Health Technology |
Ngen, Inc.
 Ngen, Inc. Medical SpecialtiesHealth Technology Ngen, Inc. advanced diagnostics provides physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop diagnostic tests for variety of diseases. Nanogen also offers a broad portfolio of patented nucleic acids chemistries and molecular tools that accelerate genomic analysis and are compatible with many systems. The SynX subsidiary offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. The company is headquartered in San Diego, CA | Health Technology |
